scholarly journals Effects of Baduanjin on glucose and lipid metabolism in diabetic patients

Medicine ◽  
2021 ◽  
Vol 100 (4) ◽  
pp. e23532
Author(s):  
Qiaojun Ma ◽  
Hanzhang Li ◽  
Yinping Gao ◽  
Yalan Zou
1993 ◽  
Vol 128 (3) ◽  
pp. 251-258 ◽  
Author(s):  
Per H Andersen ◽  
Bjørn Richelsen ◽  
Jens Bak ◽  
Ole Schmitz ◽  
Niels S Sørensen ◽  
...  

In a short-term (eight days) double-blind crossover study involving 10 obese patients, the effects of dexfenfluramine on glucose and lipid metabolism were examined. The protocol comprised whole body in vivo measurements (hyperinsulinemic euglycemic clamp in combination with indirect calorimetry) and in vitro studies of isolated adipocytes (lipolysis and glucose transport). All study participants were weight stable during the study period (103.1±3.2, placebo vs 103.3±3.1 kg, dexfenfluramine, NS). The following parameters were significantly reduced after dexfenfluramine treatment: fasting levels of plasma glucose (6.2±0.2 vs 5.7±0.2 mmol/l, p<0.01), serum insulin (168.0±14.5 vs 138.9±7.9 pmol/l, p<0.05), serum C-peptide (0.68±0.03 vs 0.58±0.02 nmol/l, p<0.05) and total serum cholesterol (6.07±0.41 vs 5.48±0.38 mmol/l, p< 0.01). In the basal state glucose oxidation rate was significantly reduced by 36% (p<0.001), whereas non-oxidative glucose disposal was significantly increased by 41% (p<0.01), following dexfenfluramine treatment. Insulin-stimulated (2 mU·kg−1·min−1) glucose disposal rate tended to be increased (18%, p=0.10) after dexfenfluramine. In conclusion, dexfenfluramine possesses beneficial regulatory effects on glucose and lipid metabolism in non-diabetic obese patients, independently of weight loss.


Drugs ◽  
1988 ◽  
Vol 36 (Supplement 1) ◽  
pp. 123-125
Author(s):  
H. U. Janka ◽  
H. Mehnert ◽  
R. Fisher ◽  
K.-U. Seiler

2008 ◽  
Vol 9 (1) ◽  
pp. 210
Author(s):  
Y. Kaneko ◽  
N. Hiroi ◽  
K. Kuboki ◽  
H. Ueshiba ◽  
N. Watanabe ◽  
...  

1985 ◽  
Vol 18 (3) ◽  
pp. 323-329
Author(s):  
Shigeko Hara ◽  
Masahiro Miura ◽  
Keihachiro Kuzuhara ◽  
Yoshio Suzuki ◽  
Hiroshi Nihei ◽  
...  

2021 ◽  
Vol 2021 ◽  
pp. 1-13
Author(s):  
Ya-nv Liu ◽  
Lin Wang ◽  
Xin Fan ◽  
Shijie Liu ◽  
Qi Wu ◽  
...  

This research review aimed to evaluate the effect of practicing Tai Chi on glucose and lipid metabolism in middle-aged and elderly diabetic patients. Furthermore, it aimed to provide a theoretical basis for the practice of Tai Chi as a way to improve glucose and lipid metabolism in middle-aged and elderly diabetic patients. Therefore, we searched for randomized controlled trials on the practice of Tai Chi in middle-aged and elderly diabetic patients in Chinese- and English-language electronic databases, such as Web of Science, PubMed, the Cochrane Library, EMBASE, Google Scholar, CNKI, Wanfang Database, and Weipu. We collected articles published no later than August 1, 2020. The methodological quality of the included studies was evaluated according to the standards of the Cochrane Collaboration System Evaluation Manual (version 5.1.0). Finally, 14 articles were included, showing an average Physiotherapy Evidence Database scale score of 6.57. The articles were meta-analyzed using Stata 14.0 software, showing that practicing Tai Chi improved middle-aged and elderly diabetic patients’ fasting blood glucose (WMD = −0.60, 95% CI [−1.08, −0.12], p = 0.015 ), glycosylated hemoglobin (WMD = −0.87, 95% CI [−1.60, −0.14], p = 0.019 ), total cholesterol (WMD = −0.48, 95% CI [−0.83, −0.14], p = 0.006 ), triglycerides (WMD = −0.21, 95% CI [−0.37, −0.04], p = 0.014 ), and low-density lipoprotein cholesterol level significantly (WMD = −0.32, 95% CI [−0.63,−0.00], p = 0.050 ). Conversely, patients’ high-density lipoprotein cholesterol levels (WMD = 0.09, 95% CI [−0.01, 0.17], p = 0.136 ) showed no obvious improvement. In conclusion, practicing Tai Chi in sessions lasting longer than 50 minutes (at least three times per week, for at least 12 weeks) can effectively improve glucose and lipid metabolism in middle-aged and elderly diabetic patients. However, several other factors affect glucose and lipid metabolism; therefore, further high-quality research is needed. Protocol registration number: INPLASY2020120107.


2010 ◽  
Vol 35 (6) ◽  
pp. 797-804 ◽  
Author(s):  
Cui-Feng Zhu ◽  
Guan-Zhi Li ◽  
Hong-Bin Peng ◽  
Fan Zhang ◽  
Yun Chen ◽  
...  

This study was aimed at examining the therapeutic effects of marine collagen peptides (MCPs) from fish hydrolysate in Chinese patients with type 2 diabetes mellitus (T2DM). A total of 100 diabetic patients and 50 healthy controls were recruited. Diabetic patients were randomized into treatment and control groups. The patients in the treatment group received an additional 13 g of MCPs daily for 3 months. Their blood samples were collected before, and 1.5 and 3 months after, treatment to evaluate glucose and lipid metabolism. The levels of serum high-sensitivity C-reactive protein (hs-CRP), nitric oxide (NO), bradykinin, prostacyclin (PGI2), and adipokines were determined. Significantly reduced levels of fasting blood glucose, human glycated hemoglobin A1c (GHbA1c), fasting blood insulin, total triglycerides, total cholesterol, low-density lipoprotein, and free-fatty acids, but increased levels of insulin sensitivity index and HDL were observed in T2DM patients following treatment with MCPs for 1.5 and 3 months. The values of these measures were significantly lower or higher than those of patient controls (p < 0.01), respectively. Interestingly, significantly decreased levels of hs-CRP and NO, but increased levels of bradykinin, PGI2, and adiponectin were detected in MCP-treated T2DM patients (p < 0.01), as compared with their basal values or the levels in patient controls. MCP treatment improved glucose and lipid metabolism in diabetic patients.


Sign in / Sign up

Export Citation Format

Share Document